244 related articles for article (PubMed ID: 18990767)
1. Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case-control study.
Sonestedt E; Borgquist S; Ericson U; Gullberg B; Olsson H; Adlercreutz H; Landberg G; Wirfält E
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3241-51. PubMed ID: 18990767
[TBL] [Abstract][Full Text] [Related]
2. Plasma enterolactone and breast cancer incidence by estrogen receptor status.
Olsen A; Knudsen KE; Thomsen BL; Loft S; Stripp C; Overvad K; Møller S; Tjønneland A
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2084-9. PubMed ID: 15598765
[TBL] [Abstract][Full Text] [Related]
3. Plant foods and oestrogen receptor alpha- and beta-defined breast cancer: observations from the Malmo Diet and Cancer cohort.
Sonestedt E; Borgquist S; Ericson U; Gullberg B; Landberg G; Olsson H; Wirfält E
Carcinogenesis; 2008 Nov; 29(11):2203-9. PubMed ID: 18711147
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
5. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland.
Pietinen P; Stumpf K; Männistö S; Kataja V; Uusitupa M; Adlercreutz H
Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):339-44. PubMed ID: 11319174
[TBL] [Abstract][Full Text] [Related]
6. An incident case-referent study on plasma enterolactone and breast cancer risk.
Hultén K; Winkvist A; Lenner P; Johansson R; Adlercreutz H; Hallmans G
Eur J Nutr; 2002 Aug; 41(4):168-76. PubMed ID: 12242585
[TBL] [Abstract][Full Text] [Related]
7. Plasma enterolactone and genistein and the risk of premenopausal breast cancer.
Piller R; Chang-Claude J; Linseisen J
Eur J Cancer Prev; 2006 Jun; 15(3):225-32. PubMed ID: 16679865
[TBL] [Abstract][Full Text] [Related]
8. Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study.
Kilkkinen A; Virtamo J; Virtanen MJ; Adlercreutz H; Albanes D; Pietinen P
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1209-12. PubMed ID: 14652283
[TBL] [Abstract][Full Text] [Related]
9. Expression of ERalpha and ERbeta in lobular carcinoma in situ.
Middleton LP; Perkins GH; Tucker SL; Sahin AA; Singletary SE
Histopathology; 2007 Jun; 50(7):875-80. PubMed ID: 17543077
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
[TBL] [Abstract][Full Text] [Related]
11. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer.
Borgquist S; Holm C; Stendahl M; Anagnostaki L; Landberg G; Jirström K
J Clin Pathol; 2008 Feb; 61(2):197-203. PubMed ID: 18223096
[TBL] [Abstract][Full Text] [Related]
12. Urinary phytoestrogens and postmenopausal breast cancer risk.
den Tonkelaar I; Keinan-Boker L; Veer PV; Arts CJ; Adlercreutz H; Thijssen JH; Peeters PH
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):223-8. PubMed ID: 11303591
[TBL] [Abstract][Full Text] [Related]
13. Serum enterolactone and prognosis of postmenopausal breast cancer.
Buck K; Vrieling A; Zaineddin AK; Becker S; Hüsing A; Kaaks R; Linseisen J; Flesch-Janys D; Chang-Claude J
J Clin Oncol; 2011 Oct; 29(28):3730-8. PubMed ID: 21900115
[TBL] [Abstract][Full Text] [Related]
14. Expression of ERalpha, ERbeta and Ki-67 in primary tumors and lymph node metastases in breast cancer.
Koda M; Sulkowski S; Kanczuga-Koda L; Surmacz E; Sulkowska M
Oncol Rep; 2004 Apr; 11(4):753-9. PubMed ID: 15010868
[TBL] [Abstract][Full Text] [Related]
15. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status.
Zaineddin AK; Vrieling A; Buck K; Becker S; Linseisen J; Flesch-Janys D; Kaaks R; Chang-Claude J
Int J Cancer; 2012 Mar; 130(6):1401-10. PubMed ID: 21544804
[TBL] [Abstract][Full Text] [Related]
16. Alcohol and breast cancer risk defined by estrogen and progesterone receptor status: a case-control study.
Deandrea S; Talamini R; Foschi R; Montella M; Dal Maso L; Falcini F; La Vecchia C; Franceschi S; Negri E
Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2025-8. PubMed ID: 18708394
[TBL] [Abstract][Full Text] [Related]
17. Variation in fasting and non-fasting serum enterolactone concentrations in women of the Malmö Diet and Cancer cohort.
Sonestedt E; Ericson U; Gullberg B; Peñalvo JL; Adlercreutz H; Wirfält E
Eur J Clin Nutr; 2008 Aug; 62(8):1005-9. PubMed ID: 17538540
[TBL] [Abstract][Full Text] [Related]
18. Dietary lignan intakes and risk of breast cancer by tumor estrogen receptor status.
McCann SE; Kulkarni S; Trevisan M; Vito D; Nie J; Edge SB; Muti P; Freudenheim JL
Breast Cancer Res Treat; 2006 Oct; 99(3):309-11. PubMed ID: 16541305
[TBL] [Abstract][Full Text] [Related]
19. Plasma enterolignan concentrations and colorectal cancer risk in a nested case-control study.
Kuijsten A; Hollman PC; Boshuizen HC; Buijsman MN; van 't Veer P; Kok FJ; Arts IC; Bueno-de-Mesquita HB
Am J Epidemiol; 2008 Mar; 167(6):734-42. PubMed ID: 18192676
[TBL] [Abstract][Full Text] [Related]
20. Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study.
Guglielmini P; Rubagotti A; Boccardo F
Breast Cancer Res Treat; 2012 Apr; 132(2):661-8. PubMed ID: 22094938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
